Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Relmada Therapeutics (RLMD)
NASDAQ:RLMD
RESEARCH TOOLSreports
Holding RLMD?
Track your performance easily
RLMD Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$1.88 - $7.22
Previous Close$2.8
Volume142.23K
Average Volume (3M)186.44K
Market Cap
$84.49M
Enterprise Value$30.37M
Total Cash (Recent Filing)$54.12M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta2.05
Next Earnings
Mar 25, 2025EPS Estimate
-$0.68Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.87
Shares Outstanding30,174,202
10 Day Avg. Volume141,314
30 Day Avg. Volume186,445
Standard Deviation0.23
R-Squared0.00850
Alpha-0.00413
Financial Highlights & Ratios
Price to Book (P/B)1.80
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-1.40
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-0.34
Forecast
1Y Price Target
$15.33Price Target Upside447.50% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
Relmada Therapeutics News
PremiumCompany Announcements
Relmada Therapeutics Inc. Reports Q3 2024 Financial ResultsBulls Say, Bears Say
Bulls Say
Clinical TrialsManagement's optimizations in site and patient selections for the RELIANCE II and Relight Phase 3 trials increase the likelihood of positive outcomes.
EarningsRelmada reported a better-than-expected GAAP EPS of -$0.59 (vs -$0.79. Mizuho/-$0.83 Cons) for 2Q24.
Financial PerformanceAs of June 30, the company had ~$70M in cash, which management believes is enough to fund operations through key milestones into 2025.
Bears Say
Analyst DowngradeAnalyst downgrades RLMD from Neutral to Sell and lowers the 12-month price target to $2 from $3 due to increased risk associated with the Ph3 RELIANCE II trial.
Psychiatrist HesitationKey opinion leaders express hesitation to prescribe REL-1017, even if approved, due to lingering concerns over abuse potential.
Trial ExecutionPotential impact from the same trial execution missteps that led to the failure of the two prior Ph3 RELIANCE I and RELIANCE III trials is noted.
---
Ownership Overview
2.40% Insiders
7.26% Mutual Funds
15.36% Other Institutional Investors
69.24% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
RLMD FAQ
What was Relmada Therapeutics’s price range in the past 12 months?
Relmada Therapeutics lowest stock price was $1.88 and its highest was $7.22 in the past 12 months.
What is Relmada Therapeutics’s market cap?
Currently, no data Available
When is Relmada Therapeutics’s upcoming earnings report date?
Relmada Therapeutics’s upcoming earnings report date is Mar 25, 2025 which is in 119 days.
How were Relmada Therapeutics’s earnings last quarter?
Relmada Therapeutics released its earnings results on Nov 07, 2024. The company reported -$0.72 earnings per share for the quarter, missing the consensus estimate of -$0.675 by -$0.045.
Is Relmada Therapeutics overvalued?
According to Wall Street analysts Relmada Therapeutics’s price is currently Undervalued.
Does Relmada Therapeutics pay dividends?
Relmada Therapeutics does not currently pay dividends.
What is Relmada Therapeutics’s EPS estimate?
Relmada Therapeutics’s EPS estimate is -$0.68.
How many shares outstanding does Relmada Therapeutics have?
Relmada Therapeutics has 30,174,202 shares outstanding.
What happened to Relmada Therapeutics’s price movement after its last earnings report?
Relmada Therapeutics reported an EPS of -$0.72 in its last earnings report, missing expectations of -$0.675. Following the earnings report the stock price went up 0.613%.
Which hedge fund is a major shareholder of Relmada Therapeutics?
Among the largest hedge funds holding Relmada Therapeutics’s share is Fortitude Family Office, LLC. It holds Relmada Therapeutics’s shares valued at 816.
---
Relmada Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$15.33 (447.50% Upside)
$15.33 (447.50% Upside)
Insider Transactions
Bought Shares
Worth $642.8K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 5.0%
Last 30 Days ▲ 18.0%
Last 30 Days ▲ 18.0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-1.75%
12-Months-Change
Fundamentals
Return on Equity
-116.60%
Trailing 12-Months
Asset Growth
-48.95%
Trailing 12-Months
Company Description
Relmada Therapeutics
Relmada Therapeutics, Inc. is a clinical-stage biotechnology company. It engages in the development of d-methadone receptor antagonist, which is a chemical entity that addresses areas of high unmet medical need in the treatment of central nervous system diseases and other disorders. The company was founded on May 31, 2012 and is headquartered in New York, NY.
---
RLMD Earnings Call
Q3 2024
0:00 / 0:00
---
RLMD Stock 12 Month Forecast
Average Price Target
$15.33
▲(447.50% Upside)
Technical Analysis
Best Analysts Covering RLMD
1 Year
1 Year Success Rate
5/19 ratings generated profit
1 Year Average Return
-19.14%
reiterated a buy rating 18 days ago
Copying Uy Ear's trades and holding each position for 1 Year would result in 26.32% of your transactions generating a profit, with an average return of -19.14% per trade.
---